• 약학회지
• /
• 제40권2호
• /
• pp.149-154
• /
• 1996

A high-performance liquid chromatographic method for the determination of ${\beta}$-sitosterol in the unsaponifiable fraction of Zea mays L. and its related drug preparations using a cholesterol as an internal standard was investigated. They were saponified with 20% methanolic KOH solution. Phytosterols in the reaction mixture were extracted with diethyl ether and separated on silica gel TLC plate with n-hexane-diethyl ether(40:60) as the solvent and then were scraped off. They were separated by reversed phase high perfomance liquid chromatography on Inertsil ODS-2 column with detection at 205nm. Cholesterol and ${\beta}$-sitosterol were resolved from interferences by adjusting the acetonitrile content in the MeOH-tetrahydrofuran-$H_2O$ eluent. The detection limit of ${\beta$-sitosterol was 0.43${\mu}$g.

• 대한치과의사협회지
• /
• 제53권7호
• /
• pp.476-484
• /
• 2015

Purpose: This study intended to analyze the validity of clinical effectiveness data of clinical trials testing systemic titrated extract of Zea Mays L. unsaponifiable fraction chemotherapeutic agent. Material and Methods: Among 5 clinical trials claimed as proof of clinical effectiveness on the Web site of the manufacturer of this chemotherapeutic agent, a review of 4 clinical trials, written in either Korean or English, was conducted. Data were extracted from studies for the following variables: year of publication, age, sample size, follow-up period, combination with contemporary periodontal treatments, randomization, randomization check, blinded measurement, and statistical test type. Results: The study subjects' age intervals were too diverse to decide a common target population to generalize the findings. No study stated clearly the rationale for the sample size determination. Follow-up period to observe the start of clinical effectiveness was inconsistent and decided without any rationale of pathophysiological latent period. Randomization to make the comparisons on the same start line was performed but failed in a study. Randomization effect was not checked in 4 studies. Performance of blinded measurement of clinical outcomes to prevent bias was unclear in 2 studies. Type of statistical test was inappropriate in 3 studies. Conclusions: Based on the analysis of the validity of data on clinical and demographic variables, the four available clinical trials have not demonstrated compelling evidence of therapeutic effectiveness of systemic titrated extract of Zea Mays L. unsaponifiable fraction chemotherapeutic agent to improve prognosis of periodontal disease either with the contemporary periodontal treatment or without it.

• 약학회지
• /
• 제44권6호
• /
• pp.578-587
• /
• 2000

The purpose of the present study was to design and prepare the optimum formulation for the oral administration of titrated extract of the unsaponifiable fraction of Zea mays L. (ETIZM). For this purpose, we simulated the blood concentration of ETIZM after its oral administration, changing the dissolution rate constants $(0.05{\sim}20\;hr^{-1})$. In vivo parameters, such as absorption rate constant $(k_a)$, elimination rate constant (k) and volume of distribution (Vd), were incorporated in the simulation on the basis of the experiments and literatures. When the dissolution rate constant $(k_r)$ is over $5\;hr^{-1}$, the absorption process appears to be the rate limiting step for the transport of ETIZM from the G.I. ract to the blood circulation. While less than $5\;hr^{-1}$, the dissolution rate considered to be the rate limiting step. Moreover, the optimum blood concentration was shown in the range from 1 to $5\;hr^{-1}$ of $k_r$ in the simulation. To design and prepare the tablets on the basis of the above results, 7 formula containing HPMC, PEG 4000 and PEG 6000 (1-5%, respectively) were prepared and evaluated. The tablets containing PEG 4000 (1%), PEG 6000 (1%) or PEG 4000 (5%) satisfy the optimum $k_r$ range ($1-5\;hr^{-1}$). These formulations, therefore, will be able to show the more effective blood concentration, compared with the commercial products after the oral administration.

• Journal of Periodontal and Implant Science
• /
• 제19권1호
• /
• pp.131.2-131.2
• /
• 1989

• Journal of Periodontal and Implant Science
• /
• 제21권2호
• /
• pp.185.2-185.2
• /
• 1991

• Journal of Periodontal and Implant Science
• /
• 제22권1호
• /
• pp.200.1-200.1
• /
• 1992

• 약학회지
• /
• 제18권1호
• /
• pp.11-19
• /
• 1974

A new dammarane-type triterpenoid, betulafolianediol, $C_{30}$H$_{52}$O$_{3}$, mp $165^{\circ}$[${\alpha}$]$_D$^{20}=+$20^{\circ}$, was isolated form the unsaponifiable fraction of leves of Betula latifalia $K_{OMAROV}$ (Betulaceae). From the spectral data of the betulafolianediol and its derivatives, betulafolianediol monoacetate (II) and betulafolianediol monoketone, the structure of betulafolianediol was provide to be 3${\alpha}$, 25-dioxy-dammarane-20[S]->24 [S]-epoxide.

• 한국작물학회:학술대회논문집
• /
• 한국작물학회 2004년도 춘계 학술대회지
• /
• pp.122-123
• /
• 2004

• 한국식품영양과학회지
• /
• 제14권4호
• /
• pp.365-369
• /
• 1985

참기름중(中) 부감화물은 RWE가 3.1%이고 RTE는 2.6%이며 전(全) sterol은 RTP가 0.68%이고 RTE가 0.48%이며 전(全) sterol중(中) free sterol이 37.9 $(RTP){\sim}52.7%(RTE)$로서 sterylglycoside 및 sterylester보다 그 함량(含量)이 많다. 참기름중(中) total sterol의 구성 sterol조성(組成)은 $39.3{\sim}42.9%$의 sitosterol, $13.0{\sim}17.2%$의 ${\Delta}^5-avenasterol$, $9.1{\sim}11.0%$의 campesterol 및 $7.4{\sim}11.5%$의 stigmasterol이며 $23.5{\sim}24.6%$의 미지(未知)sterol (RRT:1.35)도 함유(含有)되어 있었고 sterylglycoside는 total sterol의 sterol조성(組成)과 거의 같은 경향(傾向)이었으나 free sterol과 sterylester는 ${\Delta}^5-avenasterol$이 $8.1{\sim}11.4%$로서 campesterol 및 stigmasterol보다 함유비(含有比)가 낮았다. 한편 채유방법별(採油方法別) sterol조성(組成)은 차이(差異)가 거의 없었다.

• Applied Biological Chemistry
• /
• 제36권1호
• /
• pp.29-32
• /
• 1993

Latex(Hevea Brasiliensis)로부터 3종의 ${\alpha}-,\;{\gamma}-,\;{\delta}-tocotrienol$을 각각 분리하고, oil 상태의 각 성분을 얻었다. Tocotrienol을 분리하기 위하여, latex에서 추출한 조지방 성분의 비비누화분획으로 부터 semipreparative HPLC에 의한 분리방법을 사용하여 tocotrienol을 분리하였다. 이와 같은 분리방법을 이용하였을 때 latex에 함유된 tocotrienol의 함량은 약 400ppm이었으며, 순도는 ${\alpha}-,\;{\gamma}-,\;{\delta}-tocotrienol$ 각각 98.3, 99.3, 96.2%로 나타났다.